Folsom Aaron R, Anderson Jeffrey P, Ross Julie A
Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis, Minnesota55454-1015, USA.
Epidemiology. 2004 Jan;15(1):100-4. doi: 10.1097/01.ede.0000091606.31903.8e.
A recent meta-analysis concluded that there was no overall association between estrogen replacement therapy (ERT) and risk of epithelial ovarian cancer. However, several subsequent studies have suggested that long-term ERT could increase ovarian cancer risk.
We prospectively examined the association of ERT with epithelial ovarian cancer among 31,381 postmenopausal women in Iowa followed for 15 years.
Women who were using ERT at baseline had an elevated multivariate-adjusted relative risk of ovarian cancer (1.7; 95% confidence interval [CI] = 1.1-2.8) compared with never-users. Risk was higher among women who had been using ERT at baseline for more than 5 years (2.5; CI = 1.4-4.5). A time-dependent analysis likewise yielded a relative risk of 1.7 for current ERT use. Former ERT use was not associated with ovarian cancer incidence.
Long duration of ERT use after menopause could increase the risk of epithelial ovarian cancer.
最近的一项荟萃分析得出结论，雌激素替代疗法（ERT）与上皮性卵巢癌风险之间不存在总体关联。然而，随后的几项研究表明，长期ERT可能会增加卵巢癌风险。
我们对爱荷华州31381名绝经后妇女进行了前瞻性研究，随访15年，以检验ERT与上皮性卵巢癌之间的关联。
与从未使用过ERT的女性相比，基线时使用ERT的女性经多变量调整后的卵巢癌相对风险升高（1.7；95%置信区间[CI]=1.1-2.8）。基线时使用ERT超过5年的女性风险更高（2.5；CI=1.4-4.5）。时间依赖性分析同样得出当前使用ERT的相对风险为1.7。既往使用ERT与卵巢癌发病率无关。
绝经后长期使用ERT可能会增加上皮性卵巢癌的风险。
